Lorpucitinib - Janssen Research & Development
Alternative Names: JNJ-64251330Latest Information Update: 28 Oct 2023
At a glance
- Originator Janssen Research & Development
- Class Acetamides; Antineoplastics; Small molecules
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Familial adenomatous polyposis
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Familial-adenomatous-polyposis(In volunteers) in Belgium (PO, Tablet)
- 02 Jun 2023 Adverse events, pharmacodynamics and pharmacokinetics data from a phase Ib trial in Familial adenomatous polyposis presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 15 Feb 2023 Janssen Research & Development completes a phase I trial in Familial adenomatous polyposis in Puerto Rico, South Korea, France, USA, Germany, Spain, Netherlands (PO) (NCT05014360)